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Autoimmune diseases encompass a wide range of organ-
speciﬁc and systemic disorders with a complex etiology.
An intricate interplay of genetic, environmental, as well as
immunological factors leads to the development of these
debilitating diseases. In the absence of infections, regulatory
processes inhibit immune responses towards antigen. More-
over, the immune system has multiple levels of negative feed-
backmechanismsthatdampenimmuneresponsesandcoun-
teract establishment of chronic and destructive immunity.
These immune-regulatory functions include a broad spec-
trum of cellular and molecular mechanisms, which control
autoimmune responses. In autoimmune animal models and
in patients with autoimmune conditions, various disorders
of such regulatory mechanisms have been described. Knowl-
edge and understanding of the immunomodulatory and
pathogenic mechanisms that contribute to these conditions
can lead to the development of novel diagnostic strategies,
and future therapies, providing better life expectancies to
patients with autoimmune diseases.
In this special issue, we present original research articles,
as well as review papers on the role of derailed regulatory
mechanisms underlying autoimmune diseases.
The paper by Y. Takakubo and Y. T. Konttinen gives an
overview of the most important immune-regulatory mech-
anisms in systemic autoimmune and rheumatic diseases,
encompassing the failure of crucial tolerogenic mechanisms,
with a special emphasis on tolerogenic dendritic cells,
regulatory T and B cells, Th17 cells, inﬂammatory and
tolerogenic cytokines, and intracellular signaling pathways.
The paper also introduces the next-generation therapies,
beyond the currently used biologic therapies, targeting
derailed immune-regulatory processes.
The paper by C. L´ opez−Pedrera et al. addresses epige-
netic mechanisms of immune-regulatory functions in con-
junction with cardiovascular risk in systemic autoimmune
diseases. Epigenetic regulatory mechanisms comprise DNA
methylation, histone modiﬁcations, and microRNA activity,
which inﬂuence the development of autoimmune diseases.
Other two review articles describe novel immunopathologic
roles of diverse cytokines, chemokines, signaling molecules
and pattern-recognition receptors in systemic lupus erythe-
matosus, as well as addressing the interaction of CD154
with its various receptors, outlining the role of CD54 in the
pathogenesis of lupus and rheumatoid arthritis (RA).
Three papers present various immune-regulatory mech-
anisms in connection with RA.
The paper by J. Furuzawa-Carballeda et al. evaluates
the eﬀect of intramuscular administration of polymerized
collagen in early and established collagen-induced arthritis
(CIA) in mice and analyzes changes in Th subsets following
therapy. Polymerized-type I collagen induces upregulation
of Foxp3-expressing CD4+ regulatory T-cells and downreg-
ulates IL-17-producing CD4+ T-cells (Th17) cells in CIA.
Based on these ﬁndings, polymerized-collagen may be an
eﬀective therapeutic agent in early and established RA by
exerting down-regulation of autoimmune inﬂammation.
The paper by Y. Shi et al. shows that enhanced high
mobility group box chromosomal protein 1 (HMGB1)
expression can contribute to Th17 cell activation, and
thereby to the perpetuation of autoimmune processes in RA.
Another research article in the RA-section of the special
issue suggests the Notch pathway may be involved in the
pathophysiology of RA, by mediating TNF-α-induced IL-6
production in cultured ﬁbroblast-like synoviocytes.2 Clinical and Developmental Immunology
The paper by B. Szalay et al. assesses the phenotype
of T-cell subsets and describes early T-cell activation char-
acteristics in patients with Ankylosing Spondylitis (AS)
in conjunction to intravenous therapy with the anti-TNF
agent, inﬂiximab. The paper describes that the frequency
of Th2 and Th17 cells is higher in AS compared to healthy
individuals. This abnormal immune phenotype together
with functional disturbances of CD4+ and CD8+ cells in AS
can partially be restored by inﬂiximab administration.
The paper by D. Mieliauskaite et al. describes the
expression of IL-17, IL-23 and their receptors in minor
salivary glands of patients with primary Sj¨ ogren’s syndrome.
The paper by E. D. Abston et al. investigates the role
of virus-activated Toll-like receptor (TLR)3 and its adaptor
TRIF on the development of autoimmune coxsackievirus
B3 (CVB3) myocarditis in mice and shows that TLR3
versus TRIF deﬁciency results in altered Th2 responses that
uniquely inﬂuence the progression to chronic myocarditis.
T h ep a p e rb yB .D eP a e p ee ta l .g i v e sa no v e r v i e wo n
theTNFsuperfamilyofcytokinesinidiopathicinﬂammatory
myopathy. For each TNF family member, the possibilities for
treating inﬂammatory diseases in general and the idiopathic
inﬂammatory myopathies in particular are explored.
The paper by S.-J. Chen et al. introduces the current sta-
tus of immune-regulatory processes and immunomediated
therapeuticstrategiesformultiplesclerosisandhighlightsthe
growing evidence that Th17 cells play a pivotal role in the
complex adaptive autoimmunity of the disease and discusses
the roles of the associated immune cells and cytokines.
The paper by N. Rieber et al. presents current concepts
of hyperinﬂammation in the pathogenesis of chronic gran-
ulomatous disease (CGD). The paper summarizes the role
of reduced neutrophil apoptosis and eﬀerocytosis, dysbal-
anced innate immune receptors, altered T-cell surface redox
levels, induction of Th17 cells, the enzyme indolamine-
2,3-dioxygenase (IDO), impaired Nrf2 activity and inﬂam-
masome activation, as well as their potential therapeutic
implications in CGD.
This special issue encompasses basic, molecular mech-
anisms of immune-regulation in connection with autoim-
mune processes, cellular and molecular immune-regulatory
functions, which can aid as biomarkers for diagnostics,
as well as potential targeting of the immune-regulatory
machinery as part of future therapeutic interventions in
patients with autoimmune diseases.
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